Daniel AuClair, PhD, is the Chief Scientific Officer and Senior Vice President of Research at the Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, and is involved in the Multiple Myeloma Research Consortium (MMRC); a network of multiple myeloma centres across the USA.
Dr AuClair has been dedicated to the field of drug discovery and cancer genomics for over 20 years. After completing graduate studies at the University of Montreal, Montreal, Canada, and post-doctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Centre, Boston, MA, Dr AuClair worked in early cancer drug discovery at Bayer Healthcare. He has also previously held a Senior Management role at the Broad Institute of MIT and Harvard, where he was involved in academic and industrial collaborations based around cancer genomics.
In 2017, Dr AuClair was chosen by PharmaVoice as one of the top 100 Most Inspiring People in the life sciences industry.
Speaking on cancer genomics and drug discovery
Dr AuClair is a leading researcher with a primary focus on multiple myeloma. The MMRF’s scientific plan, which Dr AuClair oversees, is to achieve a cure for multiple myeloma through immunotherapy, investment, and data. The MMRF are gathering data through studies such as The MMRF CureCloud, the first and largest myeloma genomic dataset, and The CoMMpass Study, designed to provide as much information as possible about myeloma by studying patients longitudinally, and collecting as much data as possible.